<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Morawetz RA</dc:creator>
  <dc:creator>Rizzardi GP</dc:creator>
  <dc:creator>Glauser D</dc:creator>
  <dc:creator>Rutschmann O</dc:creator>
  <dc:creator>Hirschel B</dc:creator>
  <dc:creator>Perrin L</dc:creator>
  <dc:creator>Opravil M</dc:creator>
  <dc:creator>Flepp M</dc:creator>
  <dc:creator>von Overbeck J</dc:creator>
  <dc:creator>Glauser MP</dc:creator>
  <dc:creator>Ghezzi S</dc:creator>
  <dc:creator>Vicenzi E</dc:creator>
  <dc:creator>Poli G</dc:creator>
  <dc:creator>Lazzarin A</dc:creator>
  <dc:creator>Pantaleo G</dc:creator>
  <dc:date>1997</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Homozygous (delta ccr5/delta ccr5) and heterozygous (CCR5/delta ccr5) deletions in the beta-chemokine receptor 5 (CCR5) gene, which encodes for the major co-receptor for macrophage-tropic HIV-1 entry, have been implicated in resistance to HIV infection and in protection against disease progression, respectively. The CCR5/delta ccr5 genotype was found more frequently in long-term nonprogressors (LTNP) (31.0%) than in progressors (10.6%, p &lt; 0.0001), in agreement with previous studies. Kaplan-Meier survival analyses showed that a slower progression of disease, i.e. higher proportion of subjects with CD4+ T cell counts &gt; 500/microl (p = 0.0006) and a trend toward a slower progression to AIDS (p = 0.077), was associated with the CCR5/delta ccr5 genotype. However, when LTNP were analyzed separately, no significant differences in CD4+ T cell counts (p = 0.12) and viremia levels (p = 0.65) were observed between the wild-type (69% of LTNP) and the heterozygous (31.0%) genotypes. Therefore, there are other factors which play a major role in determining the status of nonprogression in the majority of LTNP. Furthermore, there was no evidence that the CCR5/delta ccr5 genotype was associated with different rates of disease progression in the group of progressors. Taken together, these results indicate that the CCR5/delta ccr5 genotype is neither essential nor sufficient for protection against the progression of HIV disease.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/93452</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1002/eji.1830271220</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/9464809</dc:relation>
  <dc:source>European journal of immunology. - 1997</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">HIV Infections</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">HIV-1</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Heterozygote</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Polymorphism, Genetic</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Prognosis</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Receptors, CCR5</dc:subject>
  <dc:title xmlns:ns8="xml" ns8:lang="en">Genetic polymorphism of CCR5 gene and HIV disease: the heterozygous (CCR5/delta ccr5) genotype is neither essential nor sufficient for protection against disease progression. Swiss HIV Cohort.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
